
News|Articles|November 1, 2012
Truvada (Emtricitabine/tenofovir disoproxil fumarate tablets)
New combination: FDA approved the combination tablet of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (Truvada, Gilead Sciences) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 in adults at high-risk in combination with safer sex practices.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
TrumpRx launches; some experts question its long-term value
3
PBM reform. It has finally happened
4
What exactly is managed care today?
5























